Electrochemotherapy of Gynecological Cancers

Inclusion criteria

• Local or regional relapse of gynecological tumors in which standard treatment options have been exhausted.
• Age more than 18.
• Life expectancy more than 3 month.
• Performance status Karnofsky ≥ 70 or WHO < or 2.
• Treatment free interval minimum 2 weeks.
• Patient must be mentally capable of understanding the given information and regarding treatment and any adverse reactions that may occur during treatment.
• Patient must give informed consent.
• Patient must be discussed at the multidisciplinary team before entering the trial.
• Patient should be suitable for anesthesia.

Exclusion criteria

• Visceral, bone or diffuse metastases.
• Life-threatening infection and/or heart failure and/or liver failure and/or other severe systemic pathologies.
• Significant reduction in respiratory function.
• Age less than 18 years.
• Coagulation disturbances (those who do not respond on standard treatment with vitamin-K or fresh frozen plasma).
• Cumulative dose of ≥ 400 mg/m2 bleomycin received.
• Impaired kidney function (creatinin > 150 µmol/l).
• Patients with epilepsy.
• Pregnancy.
• Patient incapable of understanding the aim of the study or disagree with the entering into the clinical study.